Piperlongumine and its analogs down-regulate expression of c-Met in renal cell carcinoma

被引:35
作者
Golovine, Konstantin [1 ]
Makhov, Peter [1 ]
Naito, Sei [1 ]
Raiyani, Henish [1 ]
Tomaszewski, Jeffrey [2 ]
Mehrazin, Reza [2 ]
Tulin, Alexei [3 ]
Kutikov, Alexander [2 ]
Uzzo, Robert G. [2 ]
Kolenko, Vladimir M. [1 ]
机构
[1] Fox Chase Canc Ctr, Canc Biol Program, Philadelphia, PA 19111 USA
[2] Fox Chase Canc Ctr, Div Urol Oncol, Dept Surg, Philadelphia, PA 19111 USA
[3] Fox Chase Canc Ctr, Canc Epigenet Program, Philadelphia, PA 19111 USA
基金
美国国家卫生研究院;
关键词
c-Met; cancer; piperlongumine; renal; ROS; PROSTATE-CANCER CELLS; FACTOR-KAPPA-B; TIVANTINIB ARQ 197; SIGNALING PATHWAY; KIDNEY CANCER; IN-VIVO; RESISTANCE; INHIBITORS; TARGET; ROS;
D O I
10.1080/15384047.2015.1026511
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The c-Met protein, a transmembrane receptor tyrosine kinase, is the product of a proto-oncogene. Its only known ligand, hepatocyte growth factor (HGF), regulates cell growth, motility, migration, invasion, proliferation, and angiogenesis. The aberrant expression of c-Met is often associated with poor prognosis in multiple cancers, including renal cell carcinoma (RCC). Silencing or inactivation of c-Met leads to decreased viability of cancer cells, thereby making ablation of c-Met signaling an attractive concept for developing novel strategies for the treatment of renal tumors. Naturally-occurring products or substances are the most consistent source of drug development. As such, we investigated the functional impact of piperlongumine (PL), a naturally occurring alkaloid present in the Long pepper (Piper longum) on c-Met expression in RCC cells and demonstrated that PL and its analogs rapidly reduce c-Met protein and RNA levels in RCC cells via ROS-dependent mechanism. PL-mediated c-Met depletion coincided with the inhibition of downstream c-Met signaling; namely Erk/MAPK, STAT3, NF-B and Akt/mTOR. As such, PL and PL analogs hold promise as potential therapeutic agents for the treatment of metastatic RCC and the prevention of postoperative RCC recurrence.
引用
收藏
页码:743 / 749
页数:7
相关论文
共 41 条
[1]   Synthesis, cellular evaluation, and mechanism of action of piperlongumine analogs [J].
Adams, Drew J. ;
Dai, Mingji ;
Pellegrino, Giovanni ;
Wagner, Bridget K. ;
Stern, Andrew M. ;
Shamji, Alykhan F. ;
Schreiber, Stuart L. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2012, 109 (38) :15115-15120
[2]  
[Anonymous], 2006, J CARCINOG, DOI DOI 10.1186/1477-3163-5-14
[3]  
[Anonymous], J CLIN ONCOL S5
[4]   VHL and HIF signalling in renal cell carcinogenesis [J].
Baldewijns, Marcella M. ;
van Vlodrop, Iris J. H. ;
Vermeulen, Peter B. ;
Soetekouw, Patricia M. M. B. ;
van Engeland, Manon ;
de Bruine, Adriaan P. .
JOURNAL OF PATHOLOGY, 2010, 221 (02) :125-138
[5]   In vivo growth inhibition of sarcoma 180 by piperlonguminine, an alkaloid amide from the Piper species [J].
Bezerra, Daniel P. ;
Pessoa, Claudia ;
de Moraes, Manoel Odorico ;
de Alencar, Nylane M. N. ;
Mesquita, Rodney O. ;
Lima, Michael W. ;
Alves, Ana Paula N. N. ;
Pessoa, Otilia Deusdenia L. ;
Chaves, Joao Henrique ;
Silveira, Edilberto R. ;
Costa-Lotufo, Leticia V. .
JOURNAL OF APPLIED TOXICOLOGY, 2008, 28 (05) :599-607
[6]   Loss of tumor suppressor protein PTEN during renal carcinogenesis [J].
Brenner, W ;
Färber, G ;
Herget, T ;
Lehr, HA ;
Hengstler, JG ;
Thüroff, JW .
INTERNATIONAL JOURNAL OF CANCER, 2002, 99 (01) :53-57
[7]   The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer [J].
Cho, Daniel ;
Signoretti, Sabina ;
Regan, Meredith ;
Mier, James W. ;
Atkins, Michael B. .
CLINICAL CANCER RESEARCH, 2007, 13 (02) :758S-763S
[8]   Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma [J].
Choueiri, Toni K. ;
Vaishampayan, Ulka ;
Rosenberg, Jonathan E. ;
Logan, Theodore F. ;
Harzstark, Andrea L. ;
Bukowski, Ronald M. ;
Rini, Brian I. ;
Srinivas, Sandy ;
Stein, Mark N. ;
Adams, Laurel M. ;
Ottesen, Lone H. ;
Laubscher, Kevin H. ;
Sherman, Laurie ;
McDermott, David F. ;
Haas, Naomi B. ;
Flaherty, Keith T. ;
Ross, Robert ;
Eisenberg, Peter ;
Meltzer, Paul S. ;
Merino, Maria J. ;
Bottaro, Donald P. ;
Linehan, W. Marston ;
Srinivasan, Ramaprasad .
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (02) :181-186
[9]   The therapy of kidney cancer with biomolecular drugs [J].
Di Lorenzo, G. ;
Buonerba, C. ;
Biglietto, M. ;
Scognamiglio, F. ;
Chiurazzi, B. ;
Riccardi, F. ;
Carteni, G. .
CANCER TREATMENT REVIEWS, 2010, 36 :S16-S20
[10]   Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer [J].
Eder, Joseph Paul ;
Woude, George F. Vande ;
Boerner, Scott A. ;
LoRusso, Patricia M. .
CLINICAL CANCER RESEARCH, 2009, 15 (07) :2207-2214